Abstract 5P
Background
Axillary lymph node metastases from adenocarcinoma or poorly differentiated carcinoma of unknown primary (CUPAx) is a rare disease in women. This subgroup shares similar biological characteristics with stage II-III breast cancer and is named occult breast cancer (OBC). This study intended to examine the clinicopathological features of OBC and compared OBC genetically with axillary lymph node metastases from breast cancer (BCAx), investigating differences in their biological behavior.
Methods
We conducted the clinical and prognostic analysis of 58 OBC patients in West China Hospital spanning from 2009 to 2021. Gemonic profiling of 12 OBC patients and 16 BCAx patients was conducted by the FoundationOne CDx (F1CDx) platform, including 324 genes along with genomic features such as TMB and MSI. Moreover, we also compared the gene mutation spectrum and relevant pathways between the two groups and both TCGA and COSMIC databases.
Results
The majority of the 58 OBC patients were HR-/HER2- subtype. OBC patients had a higher expression of breast origin-related immunohistochemical markers, such as GATA3, GCDFP15, and CK5/6. Most patients received mastectomy combined radiotherapy (50Gy/25f). OBC had a favorable overall prognosis. Radiotherapy was the independent prognostic factor in multivariate analysis (HR=0.04, 95%CI=0.00-0.85, P=0.0390). In 28 samples and 401 TCGA-BRCA patients, IRS2 only mutated in OBC (33.33%) but amplified in BCAx (11.11%) and TCGA-BRCA (1.5%). Pathway analysis revealed that BCAx had more NOTCH pathway mutations than OBC, where NOTCH3 and GATA3 was highly amplified in OBC (16.67% vs. 0%) and BCAx (16.67% vs. 0%) respectively. GATA6 only had novel mutations in BCAx (31.25%) according to the COSMIC database. Enrichment analysis showed that OBC enriched more in mammary development and PML bodies than BCAx, but less in the positive regulation of kinase activity.
Conclusions
More active treatment methods could improve the prognosis of OBC. The differential mutation genes of OBC and BCAx might be associated with their respective biological behaviors like invasiveness and prognosis. The differences in NOTCH pathway and enrichment analysis might cause the occult lesions in the OBC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University (ZYJC18022 and ZYJC21017).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
228P - Real-world data on dose adjustment of cabozantinib in advanced renal cell carcinoma
Presenter: Hemavathi Baskarane
Session: Poster Display
Resources:
Abstract
229P - The application of diffusion kurtosis imaging in predicting muscle invasion of bladder cancer: A comparison with conventional DWI
Presenter: Shuai Jiang
Session: Poster Display
Resources:
Abstract
230P - Oncological outcomes between partial cystectomy and radical cystectomy in solitary muscle invasive bladder cancer with downgraded T stage
Presenter: Ming Wei Hsu
Session: Poster Display
Resources:
Abstract
231P - BMI-predicted progression-free survival after pembrolizumab therapy for urothelial cancer: Asian version of BMI classification is suitable for Asian patients
Presenter: mirii harada
Session: Poster Display
Resources:
Abstract
232P - The immunosuppressive features of the 20S Proteasome β-subunit gene family in von Hippel-Lindau (VHL)-mutated clear cell renal cell carcinoma (ccRCC): A TCGA-based bioinformatics study
Presenter: Saja Alzghoul
Session: Poster Display
Resources:
Abstract
233P - The crosstalk between PBRM1 loss and tumor immune microenvironment (TIME) of clear cell renal cell carcinoma (ccRCC): A possible interconnection to immunotherapy response
Presenter: Ahmed Al Sharie
Session: Poster Display
Resources:
Abstract
235P - Do FGFR2 and 3 proteins have a role in the prognosis of urothelial bladder carcinoma?
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
236P - The effects of chemotherapy on body composition in patients with advanced urothelial carcinoma
Presenter: KOSUKE KITAMURA
Session: Poster Display
Resources:
Abstract
237P - Real-world analysis of adjuvant nivolumab in resected urothelial cancer: A single institute study in Taiwanese patients
Presenter: Mu-Hsin Chang
Session: Poster Display
Resources:
Abstract
238P - Enfortumab-vedotin for metastatic urothelial carcinoma refractory to platinum-based chemotherapy and immune checkpoint inhibitors: A single institution experience
Presenter: Yuki Endo
Session: Poster Display
Resources:
Abstract